Nuclear Medicine and Radiotracer Applications

•  New diagnostic tools are needed that include both novel radiopharmaceuticals and new applications of nuclear monitoring techniques. Examples that have recently expanded medical frontiers include Positron Emission Tomography (PET) in vivo imaging (example shown in Figure 3-1) and Accelerator Mass Spectrometry (AMS) that can bring attomole sensitivity to pharmacokinetic measurements within a patient.

•  New radioisotopes and radiopharmaceuticals for therapeutic applications in cancer research are needed that will allow more specific targeting of individual cancer cells when combined with next-generation drug delivery systems.

•  Alternative methods for producing and separating radioisotopes that have potential medical applications are needed, such as those produced with new accelerator systems, or from harvesting reactor produced elements.


FIGURE 3-1 A typical FDG-MR/PET image in coronal view. Magnetic resonance/Positron Emission Tomography (MR/PET) imaging of a 53-year-old female patient with suspicion for tumor recurrence of cervix cancer. (A) coronal T2 weighted inversion recovery sequence (STIR). (B) corresponding superimposition. (C) F-18 fluorodeoxyglucose (FDG) PET acquired with the whole-body MR/PET system (three bed positions, 6 min per bed, 120 min post injection of 361 MBq (9.8 mCi) FDG).

SOURCE: Schwenzer et al. 2012.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement